ChemoTech

Bolag

ChemoTech

Scandinavian ChemoTech är ett svenskt bolag som utvecklar och marknadsför medicinteknologi baserad på elektrokemoterapi för behandling av cancer. Bolaget erbjuder system och lösningar till kliniker inom onkologi och veterinärmedicin och har verksamhet på internationella marknader, bland annat i Indien och Sydostasien. Bolaget grundades 2015 och har sitt huvudkontor i Lund, Sverige.

Senaste publicering

I databasen

21 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
CMOTEC B

Scandinavian ChemoTech AB changes name to Neem’s Hill AB

Former Scandinavian ChemoTech AB, has completed the name change to Neem’s Hill AB (“Neem’s Hill” or “the Company”), which was resolved at the Annual General Meeting held on 5 May 2026. The name change has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). As a result, the Company’s ticker for trading on Nasdaq First North Growth Market will be changed to NEEMS as of 2026-07-13. The name change to Neem's Hill AB is part of the Company’s strategic expansion of its existing business activities and will be implemented gradually to ensure consistency and clarity across all communication channels.

CMOTEC B

ChemoTech’s TSE Reports 97% Complete Remission and Stronger Than Expected Clinical Results in Equine

Scandinavian ChemoTech AB provides an update regarding the clinical abstract on Tumour Specific Electroporation™ (TSE) in equine sarcoids, which was previously expected to be published in connection with ECVS 2026. The abstract “Bleomycin tumour-specific electroporation of Equine Sarcoids: 26 cases” has now been published earlier than anticipated, ahead of the European College of Veterinary Surgeons Annual Scientific Meeting, taking place July 9–11 in Liverpool. The abstract reports a 97% complete remission rate at 8 months follow-up in treated equine sarcoid lesions, with most horses treated under standing sedation.

CMOTEC B

Clinical Publication on TSE Therapy for the Treatment of Equine Sarcoids to Be Presented During ECVS

As previously announced on 18th of February 2026, Scandinavian ChemoTech’s Animal Care business area, VQ Animal Care, reminds the veterinary community that a clinical publication on the use of Tumour Specific Electroporation™ (TSE) for the treatment of equine sarcoids will be presented during the 35th Annual Scientific Meeting of the European College of Veterinary Surgeons (ECVS), taking place on July 9–11, 2026, in Liverpool, United Kingdom.

CMOTEC B

ChemoTech announces outcome of the directed issue

NOT FOR DISCLOSURE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER STATE OR JURISDICTION WHERE DISCLOSURE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES UNDER APPLICABLE LAW. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Scandinavian ChemoTech AB (publ) (“ChemoTech” or the “Company”) today announces the outcome of the directed issue of class A shares which was proposed by the shareholder Martin Jerndal on 31 March 2026 and resolved by the annual general meeting on 5 May 2026 (the “Directed Issue”). Through the Directed Issue, the Company issued 761,191 new class A shares, totalling approximately SEK 2.55 million, and the Company’s CEO, members of the board and current investors have subscribed for the new class A shares. All class A shares have been allotted, and the issue proceeds have been paid by set-off of the respective subscriber’s claim against the Company.

ChemoTech aktie: nyheter, pressmeddelanden och analys | Tickr